Who makes ABO2011 Injection?

ABO2011 Injection is developed by Suzhou Abogen Biosciences Co., Ltd..

What development phase is ABO2011 Injection in?

ABO2011 Injection is in Phase 1.

Last reviewed 2026-04-23 · How we verify

ABO2011 Injection

Suzhou Abogen Biosciences Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	ABO2011 Injection
Also known as	ABO2011, ABOD2011
Sponsor	Suzhou Abogen Biosciences Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ABO2011 Injection CI brief — competitive landscape report
ABO2011 Injection updates RSS · CI watch RSS
Suzhou Abogen Biosciences Co., Ltd. portfolio CI